Background and Purpose-Hematomas that enlarge following presentation with primary intracerebral hemorrhage (ICH) are associated with increased mortality, but the mechanisms of hematoma enlargement are poorly understood. We interpreted the presence of contrast extravasation into the hematoma after CT angiography (CTA) as evidence of ongoing hemorrhage and sought to identify the clinical significance of contrast extravasation as well as factors associated with the risk of extravasation. Methods-We reviewed the clinical records and radiographic studies of all patients with intracranial hemorrhage undergoing CTA from 1994 to 1997. Only patients with primary ICH were included in this study. Univariate and multivariate logistic regression analyses were performed to determine the associations between clinical and radiological variables and the risk of hospital death or contrast extravasation. Results-Data were available for 113 patients. Contrast extravasation was seen in 46% of patients at the time of CTA, and the presence of contrast extravasation was associated with increased fatality: 63.5% versus 16.4% in patients without extravasation (Pϭ0.011). There was a trend toward a shorter time (medianϮSD) from symptom onset to CTA in patients with extravasation (4.6Ϯ19 hours) than in patients with no evidence of extravasation (6.6Ϯ28 hours; Pϭ0.065).
M ortality in primary intracerebral hemorrhage (ICH) is high, and the risk of death is increased in patients with large clots, low Glasgow Coma Scale (GCS) score, and intraventricular blood. [1] [2] [3] [4] Hematoma enlargement after admission is also associated with poor outcome. 5 The incidence of hematoma enlargement, as assessed by CT, is approximately 14% to 20%. 5, 6 The mechanism by which hematomas enlarge is unclear, but growth is usually attributed to bleeding into the necrotic and edematous tissue surrounding the primary hemorrhage and not to continued bleeding from the initial vascular source. 7, 8 Factors associated with hematoma enlargement include a prior history of stroke, liver disease, hyperglycemia, and hypertension. 6 Appropriate blood pressure management in patients with acute ICH is controversial. On the one hand, elevated blood pressure may promote recurrent hemorrhage and thus hematoma enlargement. On the other hand, overly aggressive treatment of hypertension may decrease cerebral blood flow (CBF) to areas of the brain where perfusion may already be compromised. An ischemic penumbra, or an area characterized by a relative decrease in CBF, surrounds the core of a focal ischemic infarct. 9, 10 Whether an ischemic penumbra exists in ICH, however, is debated. Mayer and colleagues 8 showed, using single-photon emission tomography (SPECT), that blood flow in the areas surrounding the hematoma is markedly decreased, and the magnitude of this decrease is maximal within the first 24 hours after hemorrhage. Using positron emission tomography (PET), a more quantitative and reliable measure of CBF, however, regions of perfusiondependent brain tissue around the hematoma could not be identified. 11 Similar debates about the existence of a penumbra in ICH exist in animal models, and the disparities seem to depend on the techniques used to measure CBF. With hydrogen ion clearance, a relatively unreliable measure of CBF, 12, 13 evidence of penumbra around the site of ICH can be identified, 14 but with radiolabeled microspheres, the gold standard for CBF measurement, 15, 16 no evidence for an ischemic penumbra in ICH can be found. 17 In our institution, CT angiography is frequently performed in patients who present with ICH to screen for an underlying vascular abnormality. In most instances the CT angiogram (CTA) is performed at the time of ICH diagnosis. Review of these studies revealed frequent extravasation of radiographic contrast material into the hematoma. We interpreted extravasation as evidence of ongoing hemorrhage and sought to determine the clinical and radiographic characteristics of patients with contrast extravasation as well as the relationship between contrast extravasation and fatality.
Subjects and Methods

CT Angiography
Each patient was imaged according to the same protocol using a high-speed CT system (CTi or CT Advantage; General Electric. Axial non-enhanced, nonhelical 5-mm images were obtained at 7-mm intervals throughout the brain. After acquisition of the initial scan, 180 cc of nonionic iodinated contrast material (Optiray 300, Ioversol injection; Mallinkrodt Medical) was administered intravenously by power injector at 4 cc/sec. After a 20-second delay, during the arterial phase of contrast opacification, axial helical 1-mm images were obtained from the circle of Willis through the hematoma at 0.-mm intervals with a pitch of 1:1.4. Postinfusion, nonhelical, contiguous axial 5-mm images were obtained to evaluate contrast extravasation and change in clot size during the examination.
CT Review
All patients who had undergone CTA from 1994 to 1997 were identified through a radiology database. Patients with history of trauma or evidence of tumor, SAH, aneurysm, or other vascular malformation on CT scan or follow-up studies were excluded from analysis. CT scans were reviewed independently by 2 neuroradiologists (A.B.B., W.A.C.) who were blinded to the clinical data. Hematoma volume was estimated before and after contrast injection with the ABCϬ2 method. 18 The presence or absence of contrast extravasation was determined by visualization of high-density contrast within the clot or ventricular system. Extravasation was considered minimal if visible on only 1 or 2 postcontrast CT sections and extensive if present on 3 or more sections. Hematoma location (infratentorial versus supratentorial) and the presence or absence of intraventricular hemorrhage (IVH) were recorded. The amount of intraventricular hemorrhage was considered small if blood was visible in only 1 chamber and large if visible in Ͼ1 chamber. All discrepancies in qualitative evaluations were adjudicated; hematoma size was calculated as the average of both CT readers' values.
Chart Review
Clinical data were obtained through chart review by an investigator (H.M.B.) blinded to the radiological data. The following data were recorded: elapsed time from symptom onset to CTA; systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial blood pressure (MABP) at the time of CTA; prothrombin time, expressed as the international normalized ratio (INR), activated partial thromboplastin time (aPTT) and platelet count at admission; use of antithrombotic drugs (heparin, warfarin, aspirin, ticlopidine); initial GCS score; therapeutic drug use (osmotic agents, diuretics, antihypertensives) before CTA; initial partial pressure of carbon dioxide (PCO 2 ); and glucose levels. When possible, the premorbid medical history was obtained, with special reference to diabetes mellitus, hypertension, ethanol abuse, and tobacco abuse. If an intraparenchymal intracranial pressure (ICP) monitor was placed, initial ICP was recorded. Whether or not patients underwent surgical intervention (ventriculostomy, decompressive surgery) was noted.
Outcome Measures
Hospital fatality was the primary outcome measure. The presence or absence of contrast extravasation was analyzed as a secondary outcome measure.
Statistics
Univariate analyses for associations with hospital fatality or extravasation were performed with 2 test statistics for categorical and dichotomous data and the Wilcoxon Rank Sum (WRS) test statistic for continuous data. Independent associations with hospital fatality or extravasation were determined using a stepwise logistic regression model. Variables were retained in the model for PՅ0.20 and excluded if their retention resulted in loss of 10 or more cases in the final model. Continuous data are expressed as either the mean or medianϮSD. Statistical analyses were performed with SPSS version 7.0; significance was set at PϽ0.05.
Results
Clinical and radiographic data were available for 113 patients. Extravasation of radiographic contrast in to the hematoma was observed in 52 (46%) of the studies. There was a trend toward a shorter median (range) time from symptom onset to CTA in patients with extravasation, 4.6Ϯ19 hours (1.4 to 120), than in patients with no evidence of extravasation, 6.6Ϯ28 hours (0.5 to 144); WRS Pϭ0.065 ( Figure 1 ). There was significant correlation (Pϭ0.02, Spearman rank order) between initial GCS score and time to CTA. Figures 2, 3, and 4 depict the radiographic appearance of patients with no, minimal, or extensive contrast extravasation. In most cases, the contrast extravasated into the center of the hematoma, as seen in Figures 3 and 4 . Layering of contrast into a hematoma cavity was occasionally seen (Figure 3 ), but contrast extravasation into the periphery of the hematoma was almost never seen.
The overall fatality was 38.1% (43 of 113). The hospital fatality rate for patients with evidence of extravasation, 33 of 52 (63.5%), was significantly higher than in patients without 
001).
By the time of evaluation in the emergency department, 18.5% of patients had received antihypertensive medications, 33.9% had received furosemide, and 26.4% had received mannitol; use of these medications was not associated with hospital fatality. Of the 113 patients, 64 (56.6%) had an ICP monitor placed at admission. Initial mean ICP was 17.5Ϯ16.5 mm Hg; ICP was higher among patients who died (27.1Ϯ25.2 mm Hg) than those that survived (14.6Ϯ 11.8 mm Hg), although the difference failed to reach statistical significance. Mean ICP did not differ among patients with and without extravasation. Ventriculostomies, or intraventricular catheters, were placed in 26.5% of patients, and decompressive surgery was performed on 29.2% of patients. Surgery was performed on 10 patients with infratentorial hemorrhage and 23 patients with supratentorial hemorrhage. The mean GCS score of patient undergoing decompressive surgery was 7.6Ϯ5.1, not statistically different from the mean GCS of those patients not undergoing decompression (8.4Ϯ5.0). The median age of the patients undergoing surgery was significantly less than that of those not receiving surgical intervention (55.0Ϯ13.5 years versus 64.0Ϯ15.0 years; WRS Pϭ0.003). Table 1 shows the results of the univariate analyses for hospital fatality. In brief, decreased level of consciousness (as measured by GCS), contrast extravasation, increasing hematoma size, intraventricular rupture of blood, increased glucose, and increased pulse pressure were associated with the risk of hospital death. Neither the systolic blood pressure (SBP) nor the mean arterial blood pressure (MABP) was 
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associated with hospital fatality. The location of the ICH (supratentorial versus infratentorial) did not influence mortality in this univariate analysis. Patients who underwent decompressive surgery were more likely to survive. Univariate predictors of contrast extravasation include decreasing GCS, increasing hematoma size, intraventricular blood, increasing MABP, increasing SBP, pulse pressure Ͼ60 mm Hg, glucose Ͼ8.3 mmol/L (150 mg/dL), decreasing PCO 2 , and furosemide use prior to CTA. Use of antihypertensives before CTA was associated with decreased frequency of extravasation (Table 2) .
Using a backward stepwise logistic regression, variables independently associated with hospital fatality were lack of surgical intervention, GCS Յ8, infratentorial location of ICH, extravasation of contrast, and increasing hematoma size (Table 3) . Other variables included in the analysis were age, gender, pulse pressure Ͼ60 mm Hg, systolic blood pressure Ͼ180 mm Hg, glucose, time to CTA, and presence of IVH. Variables independently associated with contrast extravasation were hematoma size, GCS Յ8, and MABP Ͼ120 mm Hg (Table 3 ). Other variables included in the analysis were age, gender, use of furosemide before CTA, time to CTA, glucose Ͼ8.3 mmol/L (150 mg/dL), hematoma location (infratentorial versus supratentorial), systolic blood pressure Ͼ180 mm Hg, and pulse pressure Ͼ60 mm Hg.
Discussion
Our study showed that nearly one half of all patients who underwent CTA had active extravasation of contrast at the time of presentation and that contrast extravasation was an independent predictor of hospital fatality. As in other studies, the GCS and hematoma size at presentation were also independent predictors of fatality. 2, 19, 20 In addition, the initial GCS score and hematoma size were significantly associated with contrast extravasation. Presumably, contrast extravasation indicates ongoing hemorrhage and would therefore predispose to hematoma enlargement. Consistent with our findings, hematoma enlargement was previously observed to occur more frequently in patients with disturbed consciousness and in patients with large hematomas. 5, 6 Causality cannot be determined from observational studies such as this, but it is unlikely that a low GCS or a large hematoma would predispose to continued hemorrhage; it is more likely that continued hemorrhage produces larger hematomas that impair consciousness. Indeed, in a study in which patients underwent initial CT scan within 3 hours of symptom onset and follow-up scan 1 hour later, 26% had evidence of hematoma growth that was associated with clinical deterioration, as evidenced by a decrease in the GCS. 21 In fact, any clinical deterioration that occurs within the first 12 hours after symptom onset is usually related to hematoma growth. 22 Because hematoma enlargement occurs primarily in the initial hours after hemorrhage, 5, 6 one would expect that the risk of extravasation would be higher in patients undergoing early CTA. The median time to CTA in patients with extravasation was 4.6 hours in our study, compared with 6.6 hours in patients without extravasation, although the difference was not significant. Contrast extravasation was seen as late as 5 days after symptom onset in 1 patient.
We have no institutional guidelines for the management of hypertension in ICH, but in general, labetalol is used in an attempt to keep the MABP Ͻ120 mm Hg, and in this study contrast extravasation was independently associated with MABP Ͼ120 mm Hg. The association of contrast extravasation with hypertension is an important one and implies that elevation in blood pressure might contribute to the risk of continued hemorrhage. Elevated blood pressure at admission has been associated with increased mortality, 20, 23 increased hematoma size, 23 and hematoma enlargement. 5, 6 The bulk of recent data show no evidence for an ischemic penumbra in acute ICH, either experimentally 17 or clinically. 11 Xenon blood flow studies even suggest that some patients have focal hyperperfusion in the acute stages of ICH. 24 These data suggest that more aggressive blood pressure management in patients with ICH may be warranted, 25 and a preliminary study 11 shows that there is no compromise in CBF (as assessed by PET) in patients whom the MABP is lowered by 15%.
In our univariate analysis, hyperglycemia (glucose Ͼ8.3 mmol/L [150 mg/dL]) was associated with hematoma enlargement. The association between hyperglycemia and hematoma enlargement has been noted previously. 6 Hyperglycemia also predisposes to hemorrhagic transformation of ischemic infarcts, both spontaneously 26, 27 and after tPA administration. 28 Our univariate analysis also showed an association between increasing glucose and fatality. The association between hyperglycemia and increased morbidity and mortality following both ischemic 29 -31 and hemorrhagic stroke 19, 32 has been documented previously. The mechanism by which hyperglycemia contributes to worse outcome and predisposes to hemorrhage in stroke is unclear, but the association appears robust. The observed mortality in our study was 38.1%, consistent with other studies that report mortality to be approximately 30% to 50%. [33] [34] [35] [36] It is important to appreciate that the primary outcome measure in our study was hospital fatality, whereas other studies use 30-day, 20, 33, 34 90-day, 5, 36 or 180-day 35 fatality rates. The fatality among our patients with contrast extravasation was 63.5%. Previous studies have also reported increased fatality in patients with hematomas that enlarge after admission. 5 We also noted increased fatality in patients with infratentorial hemorrhage, an association that would be better understood if the proportions of patients with pure cerebellar hemorrhage and those with brain stem hemorrhage were known.
The incidence of contrast extravasation in our study is similar to that observed by others using different radiographic modalities. Yamaguchi et al 37 found that 42% of patients with primary ICH had contrast extravasation during intra-arterial angiography when performed within 5 hours of symptom onset. Similar rates of gadolinium extravasation into cerebral hematomas have been observed during MR scanning. 38 The literature also reports that approximately 20% of hematomas enlarge after presentation. 5, 6 This frequency is almost identical to the frequency of patients with extensive contrast extravasation (27/113ϭ23.9%) in our study. Nearly half of our patients had at least some evidence of contrast extravasation, and it is probable that CTA is more sensitive at detecting small amounts of contrast extravasation than standard CT is for appreciating small changes in hematoma size. The fact that contrast extravasation tended to occur centrally within the hematoma suggests that it is extravasating from a vascular source and not from necrotic and edematous tissue surrounding the primary hemorrhage. 7, 8 To validate our findings and the presumption that extravasation is evidence of ongoing bleeding predisposing to hematoma enlargement, a prospective study with CTA at the time of presentation and comparison of initial hematoma size with that 24 hours later could be performed.
If hematoma enlargement were due to ongoing bleeding, it should be more frequent in patients with coagulopathy, alcohol abuse, and liver disease. There were no relationships between these variables and extravasation in our study, although relationships with coagulopathy and hematoma growth have been documented. 5, 6 Our ability to confirm these findings was likely limited by the small sample size and the lack of patients with documented coagulopathy, alcohol abuse, or liver disease in this series.
This study is limited by its retrospective nature. We have no clear protocol for when and on whom to perform CTA; in general, a CTA is obtained when the hemorrhage or the clinical situation seems atypical for primary hypertensive hemorrhage or when a surgical evacuation is planned. Thus, there is likely a bias toward the type of patient who undergoes CTA in this series, as suggested by the high proportion receiving surgical intervention (nearly 30%). In addition, the institutional criteria for surgical intervention in supratentorial hemorrhage are not explicit and are often dependent on the attending physician. Thus, the relationship between mortality and lack of surgical intervention must therefore be viewed cautiously, because patients who are likely to do well (ie, younger patients with a higher GCS) are more likely to receive aggressive therapy. Furthermore, it may be less likely for medical support to be withdrawn in patients who have undergone surgical intervention. Information about functional outcome would be important.
Conclusions
This is the first study to examine the role of CTA in primary intracerebral hemorrhage. We found active extravasation of contrast in 46% of our patients. Extravasation is likely a surrogate for ongoing bleeding, and it is the most significant radiological variable associated with fatality in the multivariate model. The association between extravasation and fatality was strong and independent of the previously identified associations with admission GCS, admission hematoma size, and fatality. The risk of extravasation is increased in patients with elevated blood pressure, large hematomas, and depressed levels of consciousness. It remains unclear whether aggressive antihypertensive therapy in the acute phase of ICH would decrease the risk of extravasation, and thus mortality, but this hypothesis could be tested in a prospective randomized trial. Associations were determined using a backward stepwise logistic regression model. Variables were retained in the model for PՅ0.20 and excluded if their retention resulted in loss of Ն10 cases in the final model. For fatality, other variables included in the analysis were age, gender, pulse pressure Ͼ60 mm Hg, systolic blood pressure Ͼ180 mm Hg, glucose, time to CTA, and presence of IVH. For contrast extravasation, other variables included in the analysis were age, gender, use of furosemide before CTA, time to CTA, glucose Ͼ8.3 mmol/L (150 mg/dL), hematoma location (infratentorial versus supratentorial), systolic blood pressure Ͼ180 mm Hg, and pulse pressure Ͼ60 mm Hg.
